This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (51)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Lewy Body Disease  • Movement Disorders  • Neurology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A Case Report

Brian J. Bacskai, PhD; Matthew P. Frosch, MD, PhD; Stefanie H. Freeman, MD; Scott B. Raymond, BS; Jean C. Augustinack, PhD; Keith A. Johnson, MD; Michael C. Irizarry, MD; William E. Klunk, MD, PhD; Chester A. Mathis, PhD; Steven T. DeKosky, MD; Steven M. Greenberg, MD, PhD; Bradley T. Hyman, MD, PhD; John H. Growdon, MD

Arch Neurol. 2007;64(3):431-434.

Objective  To determine the correspondence between uptake of Pittsburgh Compound B (PiB) in life and measures of β-amyloid (Aβ) in postmortem tissue analysis.

Patient  A 76-year-old man with a clinical diagnosis of dementia with Lewy bodies underwent fluorodeoxyglucose ¹⁸F and PiB positron emission tomographic brain scans. Imaging revealed marked region specific binding of PiB and abnormal fluorodeoxyglucose uptake.

Intervention  Autopsy was performed 3 months after the PiB scan.

Results  Autopsy confirmed the clinical diagnosis; in addition, there was severe cerebral amyloid angiopathy and only moderate numbers of parenchymal Aβ plaques. Biochemical measures revealed a positive correlation between Aβ levels and regional PiB binding.

Conclusion  This report confirms that PiB detects Aβ in the living patient and demonstrates that amyloid deposited as cerebral amyloid angiopathy can be the dominant source of signal.

Author Affiliations: MassGeneral Institute for Neurodegenerative Diseases, Department of Neurology, Charlestown, Mass (Drs Bacskai, Frosch, Irizarry, Greenberg, Hyman, and Growdon and Mr Raymond); C. S. Kubik Laboratory for Neuropathology (Drs Frosch and Freeman) and Department of Radiology (Drs Augustinack and Johnson), Massachusetts General Hospital, Boston; and Departments of Psychiatry (Drs Klunk and Mathis) and Neurology (Dr DeKosky), University of Pittsburgh, Pittsburgh, Pa. Dr Irizarry is now with GlaxoSmithKline, Research Triangle Park, NC.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Pittsburgh Compound B Retention and Verification of Amyloid Deposition
David M. Holtzman
Arch Neurol. 2007;64(3):315-316.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinical syndromes associated with posterior atrophy: Early age at onset AD spectrum
Migliaccio et al.
Neurology 2009;73:1571-1578.
ABSTRACT | FULL TEXT  

Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden
Hedden et al.
J. Neurosci. 2009;29:12686-12694.
ABSTRACT | FULL TEXT  

11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease
Villemagne et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:998-1001.
ABSTRACT | FULL TEXT  

Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease
Nelissen et al.
JNM 2009;50:1251-1259.
ABSTRACT | FULL TEXT  

{beta}-Amyloid, Blood Vessels, and Brain Function
Smith and Greenberg
Stroke 2009;40:2601-2606.
ABSTRACT | FULL TEXT  

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Jack et al.
Brain 2009;132:1355-1365.
ABSTRACT | FULL TEXT  

In vivo mapping of amyloid toxicity in Alzheimer disease
Frisoni et al.
Neurology 2009;72:1504-1511.
ABSTRACT | FULL TEXT  

Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease
Buckner et al.
J. Neurosci. 2009;29:1860-1873.
ABSTRACT | FULL TEXT  

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography
Edison et al.
J. Neurol. Neurosurg. Psychiatry 2008;79:1331-1338.
ABSTRACT | FULL TEXT  

Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist
Klunk
Arch Neurol 2008;65:1281-1283.
FULL TEXT  

Assessment of {beta}-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography With Carbon 11-Labeled Pittsburgh Compound B
Leinonen et al.
Arch Neurol 2008;65:1304-1309.
ABSTRACT | FULL TEXT  

Imaging amyloid deposition in Lewy body diseases
Gomperts et al.
Neurology 2008;71:903-910.
ABSTRACT | FULL TEXT  

Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern?
Sojkova et al.
JNM 2008;49:1465-1471.
ABSTRACT | FULL TEXT  

PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease
Koivunen et al.
Brain 2008;131:1845-1853.
ABSTRACT | FULL TEXT  

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic et al.
Brain 2008;131:1630-1645.
ABSTRACT | FULL TEXT  

Carbon 11-Labeled Pittsburgh Compound B Positron Emission Tomographic Amyloid Imaging in Patients With APP Locus Duplication
Remes et al.
Arch Neurol 2008;65:540-544.
ABSTRACT | FULL TEXT  

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment
Jack et al.
Brain 2008;131:665-680.
ABSTRACT | FULL TEXT  

PIB is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis
Lockhart et al.
Brain 2007;130:2607-2615.
ABSTRACT | FULL TEXT  

A{beta} amyloid deposition in the language system and how the brain responds
Nelissen et al.
Brain 2007;130:2055-2069.
ABSTRACT | FULL TEXT  

Pittsburgh Compound B Retention and Verification of Amyloid Deposition
Holtzman
Arch Neurol 2007;64:315-316.
FULL TEXT